Biomarker Detection for Depressive Disorder Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods for depressive disorders, such as major depressive disorder (MDD), rely on subjective patient reports and lack biological markers, leading to underrecognition, inappropriate treatment, and high economic costs due to unpredictable medication side effects and misclassification.
Innovation Solution
Development of biomarkers based on gene expression profiles, specifically identifying altered levels of mRNA and protein expression in genes like ADCY3, ATP2C1, CD59, FAM46A, and TLR7, to diagnose and assess the risk of depressive disorders in adolescents and adults through blood samples using techniques like microarray analysis and quantitative RT-PCR.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If subjective patient reports are used for diagnosis, then diagnostic simplicity is maintained, but diagnostic accuracy and objectivity deteriorate
Solution Approach 1:
The patent replaces the mechanical/subjective interview-based diagnostic system with a molecular biological detection system. Gene expression profiles and protein markers are measured objectively through laboratory techniques, substituting subjective patient reports with quantifiable biological data that provides both objectivity and diagnostic precision.
Solution Approach 2:
The patent introduces biological markers (gene expression profiles and protein levels) as intermediaries between the patient's physiological state and the diagnostic conclusion. These markers serve as objective mediators that translate internal biological states into measurable diagnostic indicators, eliminating the need for subjective patient self-reporting.
2Measurement precision
If biological markers are developed, then diagnostic accuracy improves, but diagnostic complexity and cost increase
Solution Approach 1:
The patent segments the complex diagnostic problem into specific measurable components - particular gene expression profiles and protein markers associated with depressive disorders. By focusing on a defined set of biological indicators rather than comprehensive analysis, the approach maintains diagnostic accuracy while managing complexity through targeted measurement.
Solution Approach 2:
The patent changes the diagnostic parameters from subjective psychological assessments to objective molecular biological measurements. By measuring gene expression levels and protein concentrations as diagnostic parameters, the system achieves higher accuracy while using standardized laboratory techniques that can be automated and scaled.
3Reliability
If comprehensive treatment evaluation is performed, then treatment effectiveness improves, but time and resource consumption increase
Solution Approach 1:
The patent performs preliminary biological assessment through gene expression and protein marker analysis before initiating treatment. This preliminary action provides an objective baseline that guides treatment selection and enables earlier evaluation of treatment response, reducing the time needed for comprehensive treatment evaluation while improving reliability.
Data Source
AI summary
The present invention relates generally to the detection or diagnosis of depressive disorders, and provides methods and compositions useful for this purpose. In particular, the present invention provides biomarkers for the detection or diagnosis of major depressive disorder, and methods of use thereof.